Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0%~ 101.0% API Factory High Purity
Supple Temozolomide et intermedia Related;
Temozolomide CAS: 85622-93-1
4(5)-Amino-5(4)-Imidazolecarboxamide CAS: 360-97-4
5(4)-Amino-4(5)-Imidazolecarboxamide Hydrochloride CAS: 72-40-2
| Nomen chemicum | Temozolomide |
| Synonyma | 3,4-Dihydro-3-Methyl-4-Oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-Carboxamide |
| CAS Number | 85622-93-1 |
| CATTUS Number | RF-API29 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C6H6N6O2 |
| M. Pondus | 194.15 |
| Liquescens punctum | 212℃ dec. |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Album ut lux Pink Pulvis |
| Lepidium sativum | Per IR, HPLC |
| RELICTUM Solvents | Dimethyl Sulphoxide ≤0.50% |
| Substantiae cognatae | |
| immunditia AIC | ≤0.10% |
| una immunditia | ≤0.10% |
| Requiem ignoti immunditias | ≤0.30% |
| Totalis immunditias | ≤0.30% |
| Metalla gravis | ≤10ppm |
| Damnum in Siccatio | ≤0.50% |
| Residere in Ignition | ≤0.10% |
| Assay | 99.0%~ 101.0% (HPLC in exaruit basis) |
| Test Standard | Enterprise Standard |
| Consuetudinem | Active Pharmaceutical Ingredient (API) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica et elit Temozolomide (CAS: 85622-93-1) cum qualitate magna.Temozolomide (TMZ) est agens oris alkylating usus Glioblastoma Multiforme (GBM) et Astrocytoma, Melanoma metastatica.
Temozolomide est primum medicamentum efficax ore sumptum imidazolum et tetrazinum genus anticancri, quod pertinet ad secundam generationem agentis alkylati cum antitumore sine activatione hepatis post administrationem oralem.Notatur facile per penetrationem per impedimentum sanguinis cerebri, bonam tolerantiam et cum aliis medicamentis toxicitatis non superimpositam, et effectum synergisticum cum radiotherapia habens idoneum ad malignam glioma recurrentem tractandum post conventionalem curationem sicut glioblastoma multiformes tumores vel astrocytoma degenerativum.Medicamentum prima linea est ad melanomatum metastaticum curandum.
Temozolomide primum per Cancer Research UK Group redacta fuerat et deinde ad Societatem Schering-aratra (United States) ad progressionem transferendam.Novam structuram chemicam habet et ad quattuor imidazolum derivativum pertinet.Anno 1999 probatum est ut in mercatum ingrediamur in EU et in US, in quo permissa significatio in Civitatibus Foederatis maxime est ad secundum lineam tractationem de glioblastoma multiformi et degenerativi stellae gliomas et indicia probata EU est ad explicandum vel relapsum glioblastoma multiforme tractandum. quae iam conventional therapia subiecta est.Efficacia temozolomidis in glioblastoma multiformi tractando maiorem recognitionem in Europa accepit.
